Amgen reports Q1 results on May 19 with options positioning flashing the most defensive signal in months — even as short sellers quietly reduce their bets.
The standout heading into the print is in options. The put/call ratio jumped to 0.95 on May 15, nearly three standard deviations above its 20-day average of 0.86 — the most elevated defensive skew of the past year outside the 52-week high of 1.11. That's a sharp one-day move: the PCR sat at 0.85 the prior session. Demand for downside protection has risen fast, and it has done so while the stock is already under pressure — down 7% over the past month to $326.31, with another 3% shed this week alone.
Short interest tells a different story, and the contrast matters. Bears have actually been pulling back. Short interest dropped roughly 10% over the past week to 2.2% of the free float — a light level for a large-cap biotech. Borrow costs remain negligible at 0.40%, and availability is wide, indicating no squeeze dynamics in the lending market. The ORTEX short score has drifted lower all week, now at 35.6, well below its recent peak above 37. The directional move in short positioning — down sharply from a late-April peak near 13.5 million shares — suggests short sellers added exposure through mid-April and have since covered into the event, not pressed their bets.
The analyst community is broadly constructive but growing more selective. The consensus is a buy, with a mean price target of $352 — about 8% above current levels. Piper Sandler maintained its Overweight rating this week while trimming its target slightly to $427, still well above the pack. Morgan Stanley's target of $326 essentially marks the floor of Street expectations, sitting right at the current price. The bull case centres on pipeline momentum from recently launched drugs including Repatha and Tezspire, plus the potential upside from MariTide if data holds. Bears counter that losses of exclusivity on Prolia, Otezla, and Kyprolis cap the revenue ceiling in the $36–38 billion range through the end of the decade, with key pipeline catalysts still two years out. That debate — whether near-term LOE headwinds overwhelm long-term pipeline promise — is precisely the tension the May 19 print will either settle or sharpen.
One detail worth noting: the May 7 insider filings show a broad-based sell across the entire C-suite — CEO Robert Bradway, CFO Peter Griffith, CTO David Reese, and the CSO all sold on the same day at $331. The individual transaction values are small relative to total holdings, and all carry a significance score of 1 (the lowest), suggesting routine plan-driven sales rather than a directional call. The pattern is notable for its breadth, but the numbers do not point to conviction.
The earnings report is therefore less a test of whether Amgen is growing and more a test of whether management's volume and pricing guidance for the back half of 2026 gives the Street enough confidence to look through the LOE noise — and whether MariTide data updates, if any, move the needle on the longer-term story.
See the live data behind this article on ORTEX.
Open AMGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
